UY34745A - VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS - Google Patents

VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS

Info

Publication number
UY34745A
UY34745A UY0001034745A UY34745A UY34745A UY 34745 A UY34745 A UY 34745A UY 0001034745 A UY0001034745 A UY 0001034745A UY 34745 A UY34745 A UY 34745A UY 34745 A UY34745 A UY 34745A
Authority
UY
Uruguay
Prior art keywords
vaccines
dogs
disease
procedures
immunogenic composition
Prior art date
Application number
UY0001034745A
Other languages
Spanish (es)
Inventor
Robert M Lohse
Jason J Millership
Xu Zach
Patrick F M Meeus
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of UY34745A publication Critical patent/UY34745A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una composición inmunógena que comprende un fragmento antigénico de proteína OspA de Borrelia burgdorferi y una proteína quimérica que contiene fragmentos antigénicos de diferentes filotipos de proteína OspC de Borrelia burgdorferi. También se proporcionan vacunas que incorporan la composición inmunógena de la invención, así como procedimientos para prevenir la e nfermedad de Lyme en perros y/o proteger perros de la enfermedad de Lyme usando las vacunas.The present invention provides an immunogenic composition comprising an antigenic fragment of Borrelia burgdorferi OspA protein and a chimeric protein containing antigenic fragments of different Borprelia burgdorferi OspC protein filotypes. Vaccines that incorporate the immunogenic composition of the invention, as well as methods for preventing Lyme disease in dogs and / or protecting dogs from Lyme disease using vaccines are also provided.

UY0001034745A 2012-04-18 2013-04-16 VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS UY34745A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18

Publications (1)

Publication Number Publication Date
UY34745A true UY34745A (en) 2013-11-29

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034745A UY34745A (en) 2012-04-18 2013-04-16 VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS

Country Status (10)

Country Link
EP (1) EP2838555A2 (en)
JP (1) JP2015514776A (en)
CN (1) CN104379164A (en)
AR (1) AR090726A1 (en)
AU (1) AU2013249229A1 (en)
BR (1) BR112014025740A2 (en)
CA (1) CA2870179C (en)
EA (1) EA201491668A1 (en)
UY (1) UY34745A (en)
WO (1) WO2013158818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204404A4 (en) 2014-10-08 2018-06-06 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
CN110483624B (en) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 Borrelia garinii OspA protein C-terminal peptide segment and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
ATE181572T1 (en) * 1991-08-15 1999-07-15 Smithkline Beecham Biolog OSPA PROTEINS OF BORRELIA BURGDORFERI SUBGROUPS, GENES CODING FOR THEM AND VACCINES
PT1100922E (en) 1998-07-31 2008-05-30 Gundersen Lutheran Medical Fou Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
WO2009135118A2 (en) * 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
EP2838555A2 (en) 2015-02-25
EA201491668A1 (en) 2015-08-31
JP2015514776A (en) 2015-05-21
AR090726A1 (en) 2014-12-03
CN104379164A (en) 2015-02-25
BR112014025740A2 (en) 2017-07-04
WO2013158818A2 (en) 2013-10-24
AU2013249229A1 (en) 2014-10-23
CA2870179A1 (en) 2013-10-24
WO2013158818A3 (en) 2014-04-17
CA2870179C (en) 2018-09-04

Similar Documents

Publication Publication Date Title
IL267997A (en) Compositions, formulations and methods for treating ocular diseases
CO7160093A2 (en) Anti-egfr antibodies and uses thereof
BR112012005225B8 (en) USE OF AN ACTRIIB-FC FUSION PROTEIN FOR THE TREATMENT OF A DISORDER RELATED TO BONE OR ASSOCIATED WITH MUSCLE LOSS DUE TO FAULT MUSCLE GROWTH
MX2015011199A (en) Csf1 therapeutics.
AR090465A1 (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO
CL2014002549A1 (en) Anti-lgr5 and immunoconjugate antibodies; pharmaceutical formulation that contains them; treatment method in which anti-lgr5 and immunoconjugate antibodies are administered.
MX2012013261A (en) Chimeric ospa genes, proteins, and methods of use thereof.
DOP2013000235A (en) FUSION PROTEINS AND COMBINATION VACCINES THAT INCLUDE PROTEIN E AND PILINA A OF HAEMOPHILUS INFLUENZAE.
IN2014DN08676A (en)
MX2021004211A (en) Vaccine compositions.
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
ECSP13012893A (en) ASYMMETRIC UREAS AND MEDICAL USES OF THE SAME
UA114286C2 (en) Methods and compositions for vaccinating against staphylococcus aureus
BR112015020079A8 (en) COMPOSITIONS FOR ORAL CARE
CL2015003563A1 (en) Marker for acid sphingomyelinase disorders and their uses.
BR112015001843A2 (en) medical device, biodegradable matrix composition and method for treating a patient.
UY34745A (en) VACCINES AND PROCEDURES TO TREAT LYME'S DISEASE IN DOGS
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
EP2926822A4 (en) Pharmaceutical composition containing sceptridium japonicum extract for preventing or treating stroke or degenerative brain diseases
BR112017004304A2 (en) topical pteroestilbene compositions for use in treating UV-induced skin barrier function loss
GT201500230A (en) HERBICIDE COMPOSITION
BR112015010675A2 (en) block copolymers for tooth enamel protection
MX2015011053A (en) Oral care compositions.
CY1118255T1 (en) Substituted 6-amino-nicotinamides which carry a group containing KCNQ2 / 3 modulators

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526